Breaking News

BioNTech Faces NIH Heat: Notice of Default Issued Over COVID-19 Vaccine Royalties

BioNTech intends to defend itself against all allegations of breach.

On March 22, 2024, BioNTech SE, which recently named a new CCO, received a notice of default from the NIH concerning royalties and other amounts allegedly owed on sales of the company’s COVID-19 vaccine since commercialization.
 
A notice of default from the National Institutes of Health (NIH) is a legal step taken against a party that the NIH believes has failed to meet its obligations under a licensing agreement.
 
BioNTech says it “disagrees with the positions being taken by the NIH and intends to vigorously defend itself against all allegations of breach.”

More BioNTech News

BioNTech and Autolus Therapeutics recently announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs toward commercialization, pending regulatory authorizations.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters